4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.255
-0.375 (-10.33%)
Mar 31, 2025, 1:23 PM EDT - Market open
4D Molecular Therapeutics Stock Forecast
FDMT's stock price has decreased by -89.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 35, with a low estimate of 6.00 and a high estimate of 58. The average target predicts an increase of 975.27% from the current stock price of 3.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 10 | 11 | 11 | 10 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
B of A Securities | B of A Securities | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +1,128.88% | Mar 10, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +760.22% | Mar 4, 2025 |
RBC Capital | RBC Capital | Buy Maintains $39 → $35 | Buy | Maintains | $39 → $35 | +975.27% | Mar 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +1,005.99% | Mar 3, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $39 → $30 | Strong Buy | Maintains | $39 → $30 | +821.66% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
4.12M
from 37.00K
Increased by 11,029.73%
Revenue Next Year
5.94M
from 4.12M
Increased by 44.15%
EPS This Year
-3.67
from -2.98
EPS Next Year
-4.01
from -3.67
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 21.0M | 21.0M | 81.9M | ||
Avg | 4.1M | 5.9M | 32.2M | ||
Low | n/a | n/a | 2.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 56,656.8% | 410.0% | 1,279.7% | ||
Avg | 11,029.7% | 44.1% | 442.1% | ||
Low | - | - | -60.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.21 | -3.10 | -3.65 | ||
Avg | -3.67 | -4.01 | -3.95 | ||
Low | -4.15 | -5.30 | -4.52 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.